newsfilter
← Latest News
Earnings Call Transcripts·

Annual Meeting of Stockholders - RESMED INC

  • Financial Performance:
    • Core business revenue grew 7% in constant currency year-over-year for the first quarter.
    • Non-GAAP earnings per share (EPS) increased by 14%, representing double the revenue growth rate.
    • Gross profit margins improved by 50 basis points compared to the prior year.
    • Generated significant free cash flow, with over $1 billion returned to shareholders via a $936 million share buyback (including ASR) and dividends.
  • Guidance and Future Outlook:
    • Management targets double-digit annual growth through 2030.
    • Long-term goal to expand impact from the current 162 million lives changed in the last 12 months to 500 million lives by 2030.
    • Acquired product "Nedra" for Restless Leg Syndrome (RLS) is projected to grow from $20 million in revenue last year to $34 million this year.
    • Anticipates sustained momentum from large pharmaceutical partnerships driving demand for sleep therapy among patients on glucagon-like peptide (GLP) products.
  • Business Segments and Product Lines:
    • Digital Health: Maintains the largest medtech digital ecosystem with 36 million cloud-connected devices, 39 million patients, and 29 billion nights of respiratory data.
    • Supply & Accessories: Launched "Equipment Care" feature in MyAir app to proactively manage patient equipment resupply; GLP-linked patients show 11% higher therapy initiation, 3% higher 1-year resupply, and >7% higher 3-year resupply rates.
    • Product Innovation: Fabric masks (AirTouch N30i, AirTouch F40) demonstrate 6% higher adherence rates compared to silicone equivalents.
    • Inorganic Growth: Introduced Nedra, a non-invasive nerve stimulation device for RLS targeting 400 million potential users globally via VA and DME channels.
  • Market and Competitive Landscape:
    • Operates in a Total Addressable Market (TAM) of 2.7 billion people suffering from sleep apnea, insomnia, RLS, and COPD.
    • Leverages unique scale advantage with operations in 144 countries.
    • Sees a "once-in-a-generation" demand generation opportunity driven by the mainstreaming of primary care visits for GLP-based treatments.
    • Management describes the company's trajectory as resembling its pre-IPO 1994 position with strong organic growth capabilities.
  • Risks and Challenges:
    • No specific financial or operational risks were detailed in this specific transcript, which focused primarily on an Annual General Meeting (AGM) update.
    • Challenges implicit in the strategy include the integration and scaling of the newly acquired Nedra platform and maintaining adherence rates as the patient base grows.
  • Management Commentary and Tone:
    • Tone was highly confident and optimistic, characterizing the company as a "compelling investment opportunity" with high ROI.
    • Management emphasized the dual focus on changing lives and delivering financial returns, citing strong capital allocation discipline.
    • CEO Mick Farrell noted that the company is self-funding growth and does not require external capital for new initiatives.
  • Analyst Questions and Answers:
    • The Q&A session was conducted among shareholders during the virtual meeting.
    • No questions were submitted by shareholders during the designated Q&A period.
  • Other Key Points:
    • This transcript is from the 2026 Annual General Meeting of Stockholders, held virtually.
    • Shareholder proposals (director elections, auditor ratification, executive compensation) were unanimously approved.
    • The meeting confirmed the election of 10 directors, including CEO Michael Farrell and Founder Peter Farrell.
    • Management declined to provide new material public information beyond what was in recent earnings reports, focusing the update on strategic progress and product velocity.
Company
RESMED INC
Keywords
RESMED INC